Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007

Applied Health Economics and Health Policy

Volumn 8, Issue 5, 2010, Pages 301-315

  Orofino, Javier ^a   Soto, Javier ^b   Casado, Miguel A ^c   Oyagez, Itziar ^c  

^a Cellerix SA   (Spain)

^b PFIZER INC   (United States)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Cost analysis; Orphan drugs

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG COST; DRUG MARKETING; FRANCE; GERMANY; HEALTH CARE COST; HUMAN; ITALY; PREVALENCE; SPAIN; TREATMENT DURATION; UNITED KINGDOM;

EID: 77956289514     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11531880-000000000-00000     Document Type: Article

References (37)

1. Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol 2006; 61 (3): 243-245
2. Lavandeira A. Orphan drugs: legal aspects, current situation. Haemophilia 2002; 8 (3): 194-198
3. European Medicines Agency. Orphan drugs and rare diseases at a glance. London: European Medicines Agency,2007 Jul 3 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf [Accessed 2008 Dec 20]
4. European Organisation for Rare Diseases (EURORDIS). EURORDIS position paper on the WHO report on priority medicines for Europe and the world [online]. Available from URL: http://www.eurordis.org/IMG/pdf/eurordis-position-WHO- priority-medicines-dec04.pdf [Accessed 2008 Dec 20]
5. Wastfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 2006; 260 (1): 1-10
6. European Organisation for Rare Diseases (EURORDIS). Rare diseases: understanding this public health priority. Paris: EURORDIS, 2005 Nov [online]. Available from URL: http://www.eurordis.org/IMG/pdf/princeps-docu ment-EN.pdf [Accessed 2008 Dec 20]
7. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23 (1): 36-42
8. US Department of Health and Human Services, Food and Drug Administration. The orphan drug act (as amended) [online]. Available from URL: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ default.htm [Accessed 2008 Dec 20]
9. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of December 16, 1999 on orphan medicinal products. Official Journal of the European communities 2000; 43 (L18): 1-5 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L: 2000:018:0001:0005:EN:PDF [Accessed 2008 Dec 20]
10. Rinaldi A. Adopting an orphan. EMBO Rep 2005 Jun; 6 (6): 507-510
11. European Medicines Agency. Committee for Orphan Medicinal Products (COMP): overview [online]. Available from URL: http://www.emea.europa.eu/htms/ general/contacts/COMP/COMP.html [Accessed 2008 Dec 20]
12. Haffner ME. Adopting orphan drugs: two dozen years of treating rare diseases. N Engl J Med 2006; 354 (5): 445-447
13. European Medicines Agency. European Publics Assessment Reports (EPARs) for authorised medicinal products for human use. 2008 [online]. Available from URL: http://www.emea.europa.eu/htms/human/epar/eparintro.htm [Accessed 2008 Dec 20]
14. IMS Health. MIDAS, MAT. Dec 2007 [database]
15. European Commission. Enterprise and industry. Community register of orphan medicinal products for human use [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm [Accessed 2008 Dec 20]
16. European Medicines Agency. Human medicines: orphan medicinal products: summaries of opinion on orphan designation [online]. Available from URL: http://www.emea.europa.eu/htms/human/orphans/opinions.htm [Accessed 2008 Dec 20]
17. Olry A, editor. Prevalence of rare diseases: bibliographic data. Orphanet report series: rare diseases collection. 2010 May [online]. Available from URL: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of-rare-diseases-by- alphabetical-list.pdf [Accessed 2008 Dec 20]
18. All Wales Medicine Strategy Group. Final appraisal report: dexrazoxane (Savene) TopoTarget. Advice no: 0207-June 2007 [online]. Available from URL: http://www.wales.nhs.uk/sites3/Documents/371/Dexrazoxane%20FAR%20% 20website.pdf [Accessed 2008 Dec 20]
19. European Medicines Agency. COMP report to the commission in relation to article 10 of regulation 141 /2000 on orphan medicinal products. Doc. Ref. EMEA 35218/2005. London: European Medicines Agency, 2005 Jul 25 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/comp/3521805en.pdf [Accessed 2008 Dec 20]
20. Population Reference Bureau. 2007 World population data sheet [online]. Available from URL: http://www.prb.org [Accessed 2008 Dec 20]
21. The Association of the British Pharmaceutical Industry. Facts and statistics from the pharmaceutical industry: a global industry. Annual medicines expenditures per person, 2007 [online]. Available from URL: http://www.abpi.org. uk/statistics/section.asp?sect=1#2 [Accessed 2008 Dec 20]
22. European Central Bank. Euro foreign exchange reference rates [online]. Available from URL: http://www.ecb.int/stats/ex change/eurofxref/html/index.en. html [Accessed 2008 Dec 20]
23. Miles KA, Packer C, Stevens A. Quantifying emerging drugs for very rare conditions. QJM 2007; 100 (5): 291-295
24. National Institute for Health and Clinical Excellence. Appraising orphan drugs. London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/ niceMedia/pdf/smt/120705item4.pdf [Accessed 2008 Dec 20]
25. Gilman BH, Gage B, Haber S, et al. Impact of drug coverage on medical expenditures among the elderly. Health Care Financ Rev 2008; 29 (1): 103-118
26. Miller DP, Furberg CD, Small RH, et al. Controlling pre scription drug expenditures: a report of success. Am J Manag Care 2007 Aug; 13 (8): 473-480
27. Marshall DA, Douglas PR, Drummond MF, et al. Guide lines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmaco- economics 2008; 26 (6): 477-495
28. Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006; 61 (3): 355-360
29. Remuzzi G, Garattini S. Rare diseases: what's next? Lancet 2008; 371: 1978-1979
30. Schieppali A, Henter J-I, Daina E, et al. Why rare diseases are important medical and social issue. Lancet 2008; 371: 2039-2041
31. Haffner ME, Torrent-Farnell J, Meher PD. Does orphan drug legislation really answer the needs ofpatients? Lancet 2008; 371: 2041-2044
32. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331 (7523): 1016-1019
33. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224-227
34. Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 2006; 174 (2): 189-190
35. Hughes D. Rationing of drugs for rare diseases. Pharmaco-economics 2006; 24 (4): 315-316
36. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19 (11): 1103-1109
37. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: NICE [online]. Available from URL: http://www.nice.org.uk/media/C18/30/ SVJ2PUBLICATION2008.pdf [Accessed 2008 Dec 20]